Estephania Candelo Gomez

Estephania Candelo Gomez


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
GCGabriela Caicedo-Herrera
Gabriela Caicedo-Herrera
EGEstephania Candelo Gomez
Estephania Candelo Gomez
JPJuan Felipe Pinilla
Juan Felipe Pinilla
AVAndrés Vidal
Andrés Vidal
SCSantiago Cruz
Santiago Cruz
HPHarry Pachajoa
Harry Pachajoa
Background: Menkes disease is a congenital neurodegenerative disorder caused by ATP7A gene mutations. Clinical features include epilepsy, growth delay, reduced muscle strength, skin laxity, abnormal hair, and urologic abnormalities. Case presentation: We describe an infant with developmental delay, neurologic degeneration, and kinky hair. Molecular test revealed a novel heterozygous mutation in exon 21 of the ATP7A gene. The genotype and phenotype of the patient were compared with those of the patients reported in the literature. Conclusion: We propose that this mutation caused a dysfunctional protein resulting in classical Menkes disease. This case adds to the spectrum of pathogenic variants of the ATP7A gene known to cause disease.

6 July 2024 in The Laryngoscope
Verified
Journal Article
Open access
EGEstephania Candelo Gomez
Estephania Candelo Gomez
PBPeter C. Belafsky
Peter C. Belafsky
MCMauricio Corrales
Mauricio Corrales
DFD. Gregory Farwell
D. Gregory Farwell
LGLuis F. Gonzales
Luis F. Gonzales
MBMartin Birchall
Martin Birchall
Background: The loss of laryngeal function affects breathing, swallowing, and voice, thus severely compromises quality of life. Laryngeal transplantation has long been suggested as a solution for selected highly affected patients with complete laryngeal function loss.Objective: To obtain insights regarding the advantages, weaknesses, and limitations of this procedure and facilitate future advances, we collected uniform data from all known laryngeal transplants reported internationally.Methodology: A case series. Patients were enrolled retrospectively by each institutional hospital or clinic. Eleven patients with complete loss of laryngeal function undergoing total laryngeal transplantation between 1998 and 2018 were recruited.Results: After a minimum of 24 months follow‐up, three patients had died (27%), and there were two graft explants in survivors, one total and one partial, due to chronic rejection. In the remaining cases, voice was functional in 62.5% and 50% achieved decannulation. Swallowing was initially restricted, but only one patient was gastrostomy‐dependent by 6 months and all had normal or near‐normal swallowing by the end of year two after transplantation. Median follow‐up was 73 months. Functional (voice, swallowing, airway) recovery peaked between 12 and 24 months.Conclusions: Laryngeal transplantation is a complex procedure with significant morbidity. Significant improvements in quality of life are possible for highly selected individuals with end‐stage laryngeal disorders, including laryngeal neoplasia, but further technical and pharmacological developments are required if the technique is to be more widely applicable. An international registry should be created to provide better quality pooled data for analysis of outcomes of any future laryngeal transplants.Level of Evidence: 4 Laryngoscope, 134:4313–4320, 2024

20 September 2021 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
HPHarry Pachajoa
Harry Pachajoa
MAMaria Amparo Acosta
Maria Amparo Acosta
CACarlos J. Alméciga‐Díaz
Carlos J. Alméciga‐Díaz
YAYoseth Ariza
Yoseth Ariza
LDLorena Diaz‐Ordoñez
Lorena Diaz‐Ordoñez
EGEstephania Candelo Gomez
Estephania Candelo Gomez

26 December 2022 in Children
Verified
Journal Article
Open access
PDF file
LTLaura Alejandra Torres-Canchala
Laura Alejandra Torres-Canchala
DCDaniela Cleves-Luna
Daniela Cleves-Luna
OVOriana Arias Valderrama
Oriana Arias Valderrama
EGEstephania Candelo Gomez
Estephania Candelo Gomez
Maria Angelica GuerraMaria Angelica Guerra
Maria Angelica Guerra
MOManuela Olaya
Manuela Olaya
Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.

1 November 2018 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
LRLady J Ríos-Serna
Lady J Ríos-Serna
LDLorena Díaz-Ordoñez
Lorena Díaz-Ordoñez
EGEstephania Candelo Gomez
Estephania Candelo Gomez
HPHarry Pachajoa
Harry Pachajoa
Holt-Oram syndrome (HOS) is an autosomal dominant disorder characterized by congenital cardiac defects and congenital deformities of the upper limbs. Herein, we report the case of a 2-year-old patient presenting with clinical diagnostic criteria of HOS with interatrial and interventricular communication associated with hip dysplasia and upper limb reduction composed of radial ray anomaly. A novel de novo, potentially pathogenic variant in the TBX5 gene at NM_181486.2:c.243-1G>C was identified.

6 April 2022 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
LTLuis Fernando Tintinago
Luis Fernando Tintinago
WVWilliam Victoria
William Victoria
JSJuliana Escobar Stein
Juliana Escobar Stein
LGLuis Fernando Gonzales
Luis Fernando Gonzales
MFMaria Isabel Fernandez
Maria Isabel Fernandez
EGEstephania Candelo Gomez
Estephania Candelo Gomez